MannKind (MNKD) Completes Phase 1 Trial of Treprostinil Technosphere for PAH Advancing Development to Next Phase

MannKind Corporation (Nasdaq: MNKD) today announced that it has completed a Phase 1 clinical study of Treprostinil Technosphere (TreT) under an Investigational New Drug application filed with the Food and Drug Administration.